A crucial gap in the development of microbicides for HIV prevention is the absence of models predictive of safety. Previous studies have demonstrated an increased susceptibility to genital herpes in mice following repeated applications of nonoxynol-9 (N-9). This study was designed to explore the underlying mechanisms, focusing on the effects that N-9 has on genital tract epithelium and to apply this expanded model to evaluate the safety of microbicides that have been advanced to clinical trials.
Methods
Mice were treated intravaginally with formulated 3.5% N-9, 1% tenofovir, 0.5% or 2% PRO 2000, hydroxyethylcellulose (HEC) placebo or no treatment and the effect on herpes simplex virus 2 (HSV-2) susceptibility, epithelial cell architecture, junctional proteins and inflammation were assessed.
Results
Mice treated with seven daily doses of N-9, but not tenofovir, PRO 2000 or HEC, were significantly more susceptible to challenge with low doses of HSV-2; confocal microscopy demonstrated increased numbers of viral particles deep within the genital tract. N-9 disrupted the epithelium with loss of tight and adherens junctional proteins. By contrast, the epithelium was relatively preserved following tenofovir, PRO 2000 and HEC exposure. Additionally, N-9, but not the other microbicides, triggered a significant inflammatory response relative to untreated mice.
Conclusions
These findings indicate that disruption of the epithelium contributes to increased HSV-2 susceptibility and might provide a biomarker predictive of increased risk for HIV acquisition. The results are consistent with the safety outcomes of the recently completed Phase IIb clinical trial with 0.5% PRO 2000 gel, and predict that tenofovir gel will not adversely affect the genital tract.
References
1.
Van DammeL., ChandeyingV., RamjeeG.Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers.AIDS2000; 14: 85–88.
2.
HoneyK.Microbicide trial screeches to a halt.J Clin Invest2007; 117: 1116.
3.
CheckE.Scientists rethink approach to HIV gels.Nature2007; 446: 12.
4.
CohenJ.AIDS research. Promising AIDS vaccine's failure leaves field reeling.Science2007; 318: 28–29.
5.
HIV vaccine failure prompts Merck to halt trial.Nature2007; 449: 390.
6.
EcksteinP., JacksonM.C., MillmanN., SobreroA.J.Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys.J Reprod Fertil1969; 20: 85–93.
7.
SchwartzJ.L., MauckC., LaiJ.J.Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study.Contraception2006; 74: 133–140.
8.
FichorovaR.N., TuckerL.D., AndersonD.J.The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.J Infect Dis2001; 184: 418–428.
9.
SvenssonA., BellnerL., MagnussonM., ErikssonK.Role of IFN-α/β signaling in the prevention of genital herpes virus type 2 infection.J Reprod Immunol2007; 74: 114–123.
10.
SerwaddaD., GrayR.H., SewankamboN.K.Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda.J Infect Dis2003; 188: 1492–1497.
11.
CelumC., LevineR., WeaverM., WaldA.Genital herpes and human immunodeficiency virus: double trouble.Bull World Health Organ2004; 82: 447–453.
12.
MossG.B., ClemetsonD., D'CostaL.Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya.J Infect Dis1991; 164: 588–591.
13.
MyerL., WrightT.C.Jr., DennyL., KuhnL.Nested case-control study of cervical mucosal lesions, ectopy, and incident HIV infection among women in Cape Town, South Africa.Sex Transm Dis2006; 33: 683–687.
14.
LinehanM.M., RichmanS., KrummenacherC., EisenbergR.J., CohenG.H., IwasakiA.In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa.J Virol2004; 78: 2530–2536.
15.
GalenB., CheshenkoN., TuyamaA., RamratnamB., HeroldB.C.Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells.J Virol2006; 80: 12209–12218.
16.
QuayleA.J., PorterE.M., NussbaumA.A.Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract.Am J Pathol1998; 152: 1247–1258.
17.
ValoreE.V., ParkC.H., QuayleA.J., WilesK.R., McCrayP.B.Jr., GanzT.Human beta-defensin-1: an antimicrobial peptide of urogenital tissues.J Clin Invest1998; 101: 1633–1642.
18.
JohnM., KellerM.J., FamE.H.Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection.J Infect Dis2005; 192: 1731–1740.
19.
HazratiE., GalenB., LuW.Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection.J Immunol2006; 177: 8658–8666.
20.
ColeA.M.Innate host defense of human vaginal and cervical mucosae.Curr Top Microbiol Immunol2006; 306: 199–230.
21.
MayerK.H., MaslankowskiL.A., GaiF.Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.AIDS2006; 20: 543–551.
22.
KlasseP.J., ShattockR., MooreJ. P.. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.Annu Rev Med2008; 59: 455–471.
23.
CheshenkoN., KellerM.J., MasCasulloV.Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.Antimicrob Agents Chemother2004; 48: 2025–2036.
24.
Scordi-BelloI.A., MosoianA., HeC.Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.Antimicrob Agents Chemother2005; 49: 3607–3615.
25.
KarimS.A., ColettiA., RichardsonB.Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of hiv infection in women: results of the HPTN 035 trial.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada.
26.
HendricksonB.A., GuoJ., BrownI.Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection.Virology2000; 271: 155–162.
27.
GeraghtyR.J., KrummenacherC., CohenG.H., EisenbergR.J., SpearP.G.Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor.Science1998; 280: 1618–1620.
28.
TaylorJ.M., LinE., SusmarskiN.Alternative entry receptors for herpes simplex virus and their roles in disease.Cell Host Microbe2007; 2: 19–28.
29.
WangW., OwenS.M., RudolphD.L.Activity of alpha-and theta-defensins against primary isolates of HIV-1.J Immunol2004; 173: 515–520.
GuoC.J., TanN., SongL., DouglasS.D., HoW.Z.Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines.AIDS2004; 18: 1217–1218.
32.
AlbanesiC., FairchildH.R., MadonnaS.IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3.J Immunol2007; 179: 984–992.
33.
MesquitaP.M., CheshenkoN., WilsonS.S.Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.J Infect Dis2009; 200: 599–608.
34.
CheshenkoN., HeroldB.C.Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread.J Gen Virol2002; 83: 2247–2255.
35.
GalenB.T., MartinA.P., HazratiE.A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.J Infect Dis2007; 195: 1332–1339.
36.
MineshibaJ., MyokaiF., MineshibaF., MatsuuraK., NishimuraF., TakashibaS.Transcriptional regulation of β-defensin-2 by lipopolysaccharide in cultured human cervical carcinoma (HeLa) cells.FEMS Immunol Med Microbiol2005; 45: 37–44.
37.
KaiserV., DiamondG.Expression of mammalian defensin genes.J Leukoc Biol2000; 68: 779–784.
38.
LiuL., WangL., JiaH.P.Structure and mapping of the human β-defensin HBD-2 gene and its expression at sites of inflammation.Gene1998; 222: 237–244.
39.
CorbeilL.B., ChatterjeeA., ForesmanL., WestfallJ.A.Ultrastructure of cyclic changes in the murine uterus, cervix, and vagina.Tissue Cell1985; 17: 53–68.
40.
KaushicC., AshkarA.A., ReidL.A., RosenthalK.L.Progesterone increases susceptibility and decreases immune responses to genital herpes infection.J Virol2003; 77: 4558–4565.
41.
Van DammeL., RamjeeG., AlaryM.Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.Lancet2002; 360: 971–977.
42.
PhillipsD.M., ZacharopoulosV.R.Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice.Contraception1998; 57: 341–348.
43.
ConeR.A., HoenT., WongX., AbusuwwaR., AndersonD.J., MoenchT.R.Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.BMC Infect Dis2006; 6: 90.
44.
CataloneB.J., Kish-CataloneT.M., BudgeonL.R.Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.Antimicrob Agents Chemother2004; 48: 1837–1847.
FoleyJ.F., YuC.R., SolowR., YacobucciM., PedenK.W., FarberJ.M.Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes.J Immunol2005; 174: 4892–4900.
47.
DentonP.W., EstesJ.D., SunZ.Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.PLoS Med2008; 5: e16.
